Diamedica Therapeutics Incis A Clinical Stage Biopharmaceutical Company Based In Minneapolisminnesotafounded In 2000The Company Is Focused On Developing Innovative Treatments For Neurological And Kidney Diseasesparticularly Acute Ischemic Stroke And Chronic Kidney Diseasewith An Expanding Interest In Preeclampsiadiamedica Aims To Improve Patient Care Through Novel Therapeutic Approaches The Company S Lead Productdm199Is A Recombinant Form Of Human Tissue Kallikrein 1Klk1 Which Is Being Developed For Treating Acute Ischemic Strokepreeclampsiaand Other Vascular Diseasesdiamedica Emphasizes Rigorous Research And Developmentconducting Early Phase Clinical Trials To Assess The Safety And Efficacy Of Its Treatmentsthe Company Utilizes Advanced Biotechnology Platforms And Proprietary Techniques To Target Disease Mechanisms At A Molecular Levelrecent Developments Include The Initiation Of A Phase 2 Trial For Dm199 In Preeclampsiawith Preliminary Data Expected In 2025
